Cyrus Mozayeni, Vedere Bio CEO

Months af­ter No­var­tis buy­out, the old Vedere Bio team is back at it with a new pipeline and a fresh $77M

What do you do when No­var­tis plunks down $150 mil­lion to buy your start­up be­fore you even hit the clin­ic? If you’re Cyrus Moza­yeni, you …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.